Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Sabina, Russo"'
Autor:
Alessandro Allegra, Giuseppe Mirabile, Santino Caserta, Fabio Stagno, Sabina Russo, Giovanni Pioggia, Sebastiano Gangemi
Publikováno v:
Antioxidants, Vol 13, Iss 4, p 461 (2024)
The balanced reciprocal translocation t (9; 22) (q34; q11) and the BCR-ABL fusion gene, which produce p210 bcr-abl protein production with high tyrosine kinase activity, are characteristics of chronic myeloid leukemia, a myeloproliferative neoplasm.
Externí odkaz:
https://doaj.org/article/9b628f17c71141668fb1979e14500522
Autor:
Massimo Breccia, Antonella Russo Rossi, Valentina Giai, Bruno Martino, Carmen Fava, Mario Annunziata, Elisabetta Abruzzese, Gianni Binotto, Claudia Baratè, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Valeria Calafiore, Maria Cristina Carraro, Federica Cattina, Francesco Cavazzini, Maria Teresa Corsetti, Lara Crucitti, Monica Crugnola, Paolo Ditonno, Ambra DI Veroli, Anna Ermacora, Felicetto Ferrara, Angelo Genua, Antonella Gozzini, Stefana Impera, Alessandra Iurlo, Luciano Levato, Luigiana Luciano, Maria Cristina Miggiano, Marco De Gobbi, Marco Santoro, Barbara Scappini, Anna Rita Scortechini, Andrea Patriarca, Serena Rosati, Sabina Russo, Rosaria Sancetta, Grazia Sanpaolo, Teresa Maria Santeramo, Silvia Sibilla, Federica Sorà, Paolo Sportoletti, Fabio Stagno, Elena Trabacchi, Fausto Castagnetti
Publikováno v:
HemaSphere, Vol 7, p e55133e1 (2023)
Externí odkaz:
https://doaj.org/article/7ea0bb7830224451ba8d9aae8fc0796c
Autor:
Michele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, Massimiliano Bonifacio, Fabio Stagno, Gianni Binotto, Mariella D’Adda, Monia Lunghi, Monica Crugnola, Maria Luisa Ferrari, Francesca Lunghi, Fausto Castagnetti, Gianantonio Rosti, Roberto M. Lemoli, Rosaria Sancetta, Maria Rosaria Coppi, Maria Teresa Corsetti, Giovanna Rege Cambrin, Atelda Romano, Mario Tiribelli, Antonella Russo Rossi, Sabina Russo, Lara Aprile, Monica Bocchia, Lisa Gandolfi, Mirko Farina, Simona Bernardi, Nicola Polverelli, Aldo M. Roccaro, Antonio De Vivo, Michele Baccarani, Domenico Russo
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1726-1737 (2021)
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only
Externí odkaz:
https://doaj.org/article/b182193348604dd0987cace12205f347
Autor:
Alessandra Iurlo, Daniele Cattaneo, Silvia Artuso, Dario Consonni, Elisabetta Abruzzese, Gianni Binotto, Monica Bocchia, Massimiliano Bonifacio, Fausto Castagnetti, Sara Galimberti, Antonella Gozzini, Miriam Iezza, Roberto Latagliata, Luigiana Luciano, Alessandro Maggi, Maria Cristina Miggiano, Patrizia Pregno, Giovanna Rege-Cambrin, Sabina Russo, Anna Rita Scortechini, Agostino Tafuri, Mario Tiribelli, Carmen Fava, Gianantonio Rosti, Robin Foa, Massimo Breccia, Giuseppe Saglio
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Treatment-free remission (TFR) has become a primary therapeutic goal in CML and is also considered feasible by international guidelines. TKIs dose reduction is often used in real-life practice to reduce adverse events, although its impact on TFR is s
Externí odkaz:
https://doaj.org/article/65c0695e402745059fa9fbd7d9d31204
Autor:
Sabina Russo
Publikováno v:
INFAD, Vol 1, Iss 1, Pp 517-528 (2020)
Over the years, there has been a progressive increase in the number of overweight and obese people of all ages and social realities in Europe and around the world, making obesity one of the most common public health problems pressing. Obesity is a pr
Externí odkaz:
https://doaj.org/article/a2f354e0c1b9449a9ae74dc0eaee1108
Autor:
Carmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, Marco Cerrano, Paola Berchialla, Matteo Dragani, Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Bruno Martino, Carlo Gambacorti-Passerini, Elisabetta Abruzzese, Chiara Elena, Patrizia Pregno, Antonella Gozzini, Isabella Capodanno, Micaela Bergamaschi, Monica Crugnola, Monica Bocchia, Sara Galimberti, Davide Rapezzi, Alessandra Iurlo, Daniele Cattaneo, Roberto Latagliata, Massimo Breccia, Michele Cedrone, Marco Santoro, Mario Annunziata, Luciano Levato, Fabio Stagno, Francesco Cavazzini, Nicola Sgherza, Valentina Giai, Luigia Luciano, Sabina Russo, Pellegrino Musto, Giovanni Caocci, Federica Sorà, Francesco Iuliano, Francesca Lunghi, Giorgina Specchia, Fabrizio Pane, Dario Ferrero, Michele Baccarani, Giuseppe Saglio
Publikováno v:
Haematologica, Vol 104, Iss 8 (2019)
It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who disc
Externí odkaz:
https://doaj.org/article/91574ca7129b473fbd2b6a8aa9f582fd
Autor:
Isabella Capodanno, Mario Tiribelli, Maria Cristina Miggiano, Cristina Bucelli, Francesco Cavazzini, Sabrina Leonetti Crescenzi, Sabina Russo, Emilia Scalzulli, Andrea Bernardelli, Luigiana Luciano, Olga Mulas, Giuseppina Loglisci, Chiara Elena, Umberto Pizzano, Immacolata Attolico, Gianni Binotto, Elena Crisà, Paolo Sportoletti, Ambra Di Veroli, Anna Rita Scortechini, Annapaola Leporace, Maria Basile, Monica Crugnola, Fabio Stagno, Pamela Murgano, Davide Rapezzi, Debora Luzi, Alessandra Iurlo, Monica Bocchia, Carmen Fava, Alessandra Malato, Sara Galimberti, Iolanda Donatella Vincelli, Malgorzata Monika Trawinska, Michele Pizzuti, Giovanni Caocci, Massimiliano Bonifacio, Giuseppe Saglio, Giorgina Specchia, Massimo Breccia, Roberto Latagliata
Publikováno v:
Blood. 140:3920-3922
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aadc449faf8bea34f0d014198bfc996
https://doi.org/10.1182/blood-2022-164790
https://doi.org/10.1182/blood-2022-164790
Autor:
Sabina Russo, Giuseppa Penna, Arianna D’Angelo, Alessandro Allegra, Andrea Alonci, Caterina Musolino
Publikováno v:
Clinical Management Issues, Vol 5, Iss 5S, Pp 7-14 (2015)
This article describes the case of a 44 year old man, at high-risk according to the Sokal Index, after CML Ph+ diagnosis, started imatinib at the standard dose (400 mg/day). Initially he reached optimal response, but at month 12, because of a loss of
Externí odkaz:
https://doaj.org/article/3f668b47cbcb49a38a9f7ff72e1b146e
Autor:
Caterina Musolino, Alessandro Allegra, Carmen Mannucci, Sabina Russo, Andrea Alonci, Valerio Maisano, Gioacchino Calapai, Sebastiano Gangemi
Publikováno v:
Turkish Journal of Hematology, Vol 32, Iss 2, Pp 168-171 (2015)
Imatinib mesylate is a small-molecule tyrosine kinase inhibitor (TKi) designed to target c-ABL and BCR-ABL, approved for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Adverse cutaneous reactions induced by imatinib ar
Externí odkaz:
https://doaj.org/article/afc49c04de1642e59edf53877ae7701b
Autor:
Stefania Stella, Valentina Zammit, Silvia Rita Vitale, Maria Stella Pennisi, Michele Massimino, Elena Tirrò, Stefano Forte, Antonio Spitaleri, Agostino Antolino, Sergio Siracusa, Vincenzo Accurso, Donato Mannina, Stefana Impera, Caterina Musolino, Sabina Russo, Alessandra Malato, Giuseppe Mineo, Maurizio Musso, Ferdinando Porretto, Bruno Martino, Francesco Di Raimondo, Livia Manzella, Paolo Vigneri, Fabio Stagno
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 9, p 2226 (2019)
A reduction in BCR-ABL1/ABL1IS transcript levels to BCR-ABL1 thresholds in predicting treatment outcomes for 184 subjects diagnosed with CML and treated with standard-dose imatinib mesylate (IM). With a median follow-up of 61 months, patients with co
Externí odkaz:
https://doaj.org/article/338a3f71e02a4978954a592a94642302